Telemetry Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Telemetry Investments’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,743	Closed	-$44K	–	69
2019 Q2	$44K	Sell	1,743 -3,902	-69%	-$151K	0.03%	80
2019 Q1	$240K	Buy	5,645 +4,968	+734%	+$113K	0.12%	74
2018 Q4	$10K	Sell	677 -773	-53%	-$31.5K	0.01%	135
2018 Q3	$102K	Sell	1,450 -1,144	-44%	-$86.9K	0.05%	111
2018 Q2	$192K	Sell	2,594 -2,406	-48%	-$214K	0.07%	114
2018 Q1	$476K	Buy	5,000 +622	+14%	+$107K	0.18%	75
2017 Q4	$565K	Sell	4,378 -205	-4%	-$19.2K	0.22%	70
2017 Q3	$311K	Buy	4,583 +1,050	+30%	+$85.7K	0.11%	95
2017 Q2	$334K	Buy	3,533 +108	+3%	+$12.4K	0.16%	83
2017 Q1	$492K	Sell	3,425 -27	-0.8%	-$3.86K	0.22%	62
2016 Q4	$437K	Buy	+3,452	New	+$480K	0.25%	56

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Telemetry Investments's VIRX Position: Q3 2019 in Review

Telemetry Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2019, closing a stake of 1,743 shares — an estimated $44K sold.

Telemetry Investments first reported a position in VIRX in Q4 2016 and held it in 11 quarters. The position peaked at $565K in Q4 2017. 49 funds tracked by Wall St. Rank hold VIRX as of Q3 2019.

Telemetry Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Telemetry Investments sold 1,743 Viracta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $44K.
Telemetry Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2016 and held it in 11 quarters.
Telemetry Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $565K in Q4 2017.
49 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Telemetry Investments's 13F filing for Q3 2019, filed 14 Nov 2019.